Back to Search
Start Over
Peripheral neuropathy after viral eradication with direct-acting antivirals in chronic HCV hepatitis: A prospective study.
- Source :
-
Liver international : official journal of the International Association for the Study of the Liver [Liver Int] 2021 Nov; Vol. 41 (11), pp. 2611-2621. Date of Electronic Publication: 2021 Jul 20. - Publication Year :
- 2021
-
Abstract
- Background: HCV-related extra-hepatic complications include peripheral neuropathies, with important prevalence and impact. A recent metanalysis of previous intervention trials concluded for insufficient data to support evidence-based treatments for this complication. In this longitudinal study, we assessed for the first time prevalence and outcome of neuropathy in a cohort of patients with chronic HCV, before and after direct-acting antiviral agent (DAA) treatment.<br />Method: Ninety-four patients (mean age 58.5 ± 9.9, infection duration 22.2 ± 6.3 years) without systemic and metabolic diseases, underwent neurological examination and electroneurography studies before (T0) and 10.4 ± 1.7 months after the end of DAA therapy (T1), and cryoglobulins (CG) assessment. Muscle strength was evaluated by Medical Research Council (MRC) score; neuropathic pain, sensory function, disability, quality of life were assessed by validated questionnaires (DN4, NPSI, SSS, INCAT and Euro-QoL).<br />Results: At T0, sensory-motor neuropathy was detected in 22 patients (23%), reflexes were depressed in 32 (34%) with no association with infection duration, viral load, age, CG. Neuropathic pain (DN4 ≥4) was present in 37 patients (39%). At T1, out of the 22 patients with altered electroneurography, 3 had died or developed HCC, 4 showed normal electroneurography, and nerve amplitude parameters tended to improve in the whole group. Only 11 patients (12%) had depressed reflexes and 10 (11%) DN4 ≥4 (P < .05 compared to T0). Scores for MRC, questionnaires and Euro-QoL improved significantly (P < .05).<br />Conclusion: Our study confirms the high prevalence of clinical and subclinical peripheral sensory-motor neuropathy in patients with HCV infection and indicates improvement after eradication by DAA. These results support the need for larger intervention studies.<br /> (© 2021 The Authors. Liver International published by John Wiley & Sons Ltd.)
- Subjects :
- Aged
Antiviral Agents therapeutic use
Humans
Longitudinal Studies
Middle Aged
Prospective Studies
Quality of Life
Carcinoma, Hepatocellular drug therapy
Hepatitis C drug therapy
Hepatitis C, Chronic complications
Hepatitis C, Chronic drug therapy
Liver Neoplasms drug therapy
Peripheral Nervous System Diseases drug therapy
Peripheral Nervous System Diseases epidemiology
Peripheral Nervous System Diseases etiology
Subjects
Details
- Language :
- English
- ISSN :
- 1478-3231
- Volume :
- 41
- Issue :
- 11
- Database :
- MEDLINE
- Journal :
- Liver international : official journal of the International Association for the Study of the Liver
- Publication Type :
- Academic Journal
- Accession number :
- 34219359
- Full Text :
- https://doi.org/10.1111/liv.15002